Immatics is planning to advance two T cell receptor-based bispecific antibodies based on results reported Wednesday across Phase 1 trials.

The company’s bispecific work previously faced questions when Bristol Myers Squibb …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844